Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions
Donna M. Conlon, Carolin V. Schneider, Yi-An Ko, Amrith Rodrigues, Kathy Guo, Nicholas J. Hand, Daniel J. Rader
Donna M. Conlon, Carolin V. Schneider, Yi-An Ko, Amrith Rodrigues, Kathy Guo, Nicholas J. Hand, Daniel J. Rader
View: Text | PDF
Research Article Genetics Vascular biology

Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions

  • Text
  • PDF
Abstract

Genetic variants at the SORT1 locus in humans, which cause increased SORT1 expression in the liver, are significantly associated with reduced plasma levels of LDL cholesterol and apolipoprotein B (apoB). However, the role of hepatic sortilin remains controversial, as genetic deletion of sortilin in mice has resulted in variable and conflicting effects on apoB secretion. Here, we found that Sort1-KO mice on a chow diet and several Sort1-deficient hepatocyte lines displayed no difference in apoB secretion. When these models were challenged with high-fat diet or ER stress, the loss of Sort1 expression resulted in a significant increase in apoB-100 secretion. Sort1-overexpression studies yielded reciprocal results. Importantly, carriers of SORT1 variant with diabetes had larger decreases in plasma apoB, TG, and VLDL and LDL particle number as compared with people without diabetes with the same variants. We conclude that, under basal nonstressed conditions, loss of sortilin has little effect on hepatocyte apoB secretion, whereas, in the setting of lipid loading or ER stress, sortilin deficiency leads to increased apoB secretion. These results are consistent with the directionality of effect in human genetics studies and suggest that, under stress conditions, hepatic sortilin directs apoB toward lysosomal degradation rather than secretion, potentially serving as a quality control step in the apoB secretion pathway in hepatocytes.

Authors

Donna M. Conlon, Carolin V. Schneider, Yi-An Ko, Amrith Rodrigues, Kathy Guo, Nicholas J. Hand, Daniel J. Rader

×

Figure 4

In cells overexpressing human apoB or treated with fatty acids loss of sortilin results in a significant increase in apoB-100 secretion.

Options: View larger image (or click on image) Download as PowerPoint
In cells overexpressing human apoB or treated with fatty acids loss of s...
(A) McA and McA-HAPOB cells were transfected with rat Sort1 (rSort1) siRNA or control siRNA. After 36 hours, cells were incubated for 1 hour without Met/Cys and then labeled in the same media with 35S Met/Cys for 2 hours. Media was collected and cells were lysed and subjected to autoradiography, and 35S-labeled apoB-100 was quantified by liquid scintillation counting counted. n = 3 wells/group. Representative of 3 independent experiments. (B) McA and McA-HAPOB cells were transfected with mSort1 or empty control vector (pcDNA), and apoB-100 secretion was measured as described in A. n = 3 wells/group. Representative of 3 independent experiments. (C) siRNA-transfected McA cells were incubated without Met/Cys with 0(NT), 0.4, 0.8, or 1.2 mM oleic acid (OA) for 2 hours and then labeled in the same media with 35S Met/Cys for 2 hours, after which apoB-100 secretion was measured. n = 9 wells/treatment/group. (D) apoB secretion from McA cells treated with 0, 0.4 mM, or 0.8 mM palmitic acid (PA). n = 9 wells/treatment/group. (E) apoB secretion in siRNA-transfected HepG2 cells treated with 0 or 1.2 mM OA. n = 9 well/treatment/group. (F) apoB secretion in primary hepatocytes isolated from Sort1-KO mice and WT littermate controls treated with 0.4 mM OA or 0.4 mM PA or nontreated (NT) for 4 hours. n = 3 wells/mouse. Representative of 3 independent isolations. *P < 0.05 versus control siRNA or pcDNA by ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts